Go Pro
→ Ray Dalio: Buy Gold. Get Paid. (From Investors Alley) (Ad)tc pixel Free FATE Stock Alerts

Fate Therapeutics (FATE) Earnings Date, Estimates & Call Transcripts

Fate Therapeutics logo
$2.54 +0.02 (+0.60%)
As of 02:28 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

Fate Therapeutics Earnings Summary

Fate Therapeutics posted Q2 2026 earnings on August 13, 2026, reporting an EPS of -$0.25, which beat the consensus estimate of -$0.26 by $0.01. Quarterly revenue was reported to be $2.08 million, above analysts' expectations of $1.37 million. With a trailing EPS of -$1.09, Fate Therapeutics' earnings are expected to grow next year, from ($1.04) to ($0.99) per share.

Upcoming Q3
Earnings Date
Oct. 29Before Market OpensEstimated
Consensus EPS
(Aug. 13)
-$0.26
Actual EPS
(Aug. 13)
-$0.25 Beat By $0.01
Actual Revenue
(Aug. 13)
$2.08M

Q2 2026 Earnings Resources

FATE Upcoming Earnings

Fate Therapeutics' next earnings date is estimated for Thursday, October 29, 2026, based on past reporting schedules.

Powered by Quartr
Get Fate Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

FATE Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FATE Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Fate Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20262-$0.34-$0.28-$0.31
Q2 20262-$0.35-$0.27-$0.31
Q3 20262-$0.29-$0.28-$0.29
Q4 20262-$0.30-$0.28-$0.29

Fate Therapeutics Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
10/29/2026
(Estimated)		--------
8/13/2026Q2 2026-$0.2573-$0.25+$0.0073-$0.25$1.37M$2.08M
5/13/2026Q1 2026-$0.29-$0.26+$0.03-$0.26$1.49M$1.30M
2/26/2026Q4 2025-$0.27-$0.27--$0.27$1.20M$1.37M
11/13/2025Q3 2025-$0.29-$0.27+$0.02-$0.27$1.63M$1.74M
8/12/2025Q2 2025-$0.35-$0.29+$0.06-$0.29$1.16M$1.91M
5/13/2025Q1 2025-$0.39-$0.32+$0.07-$0.32$1.18M$1.63M
3/5/2025Q4 2024-$0.44-$0.31+$0.13-$0.44$1.57M$1.86M
11/12/2024--$0.42-$0.40+$0.02-$0.40$0.88M$3.07M

Fate Therapeutics Earnings - Frequently Asked Questions

Fate Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 29th, 2026 based off last year's report dates. Learn more on FATE's earnings history.

In the previous quarter, Fate Therapeutics (NASDAQ:FATE) reported ($0.25) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.26) by $0.01. Learn more on analysts' earnings estimate vs. FATE's actual earnings.

Fate Therapeutics (NASDAQ:FATE) has a recorded annual revenue of $6.32 million.

Fate Therapeutics (NASDAQ:FATE) has a recorded net income of -$136.32 million. FATE has generated -$1.09 earnings per share over the last four quarters.

Fate Therapeutics' earnings are expected to grow from ($1.04) per share to ($0.99) per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:FATE is sourced from Fiscal.ai, with the most recent quarter reported on 8/13/2026. New results are added as companies report their earnings.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Why I'm sending this one to my own family
Behind the Markets editor Kelly Maguire says she has never sent an email quite like this one. A sealed congres...
Behind the Markets | Sponsoredtc pixel
Central banks bought 710 tonnes - this fund pays monthly
Gold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Why November 27 Is Quickly Becoming America's Most Important Financial Date in Decades
An estimated $10 trillion could move through a little known government initiative, according to analyst Joel L...
Altimetry | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
Gold buyout deals have handed shareholders overnight gains up to 79 percent
Gold major acquisitions have repriced junior miners overnight, with past deals delivering gains from 40% to 1,...
Golden Portfolio | Sponsoredtc pixel